A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG)

"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."

"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days."

"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."